Background Current risk scores inadequately predict long-term mortality after transcatheter aortic valve replacement (TAVR), ...

Patients with severe aortic stenosis at low surgical risk who underwent supra-annular, self-expanding Evolut transcatheter aortic valve replacement (TAVR) had similar rates of death or disabling ...

The PROTECTED TAVR trial investigated the use of CEP to prevent stroke related to transcatheter aortic-valve replacement ... age of the participants was 81.2±6.5 years, and 38.7% were women.

Edwards Lifesciences announced the FDA approved its transcatheter aortic valve replacement platform for treatment of severe asymptomatic aortic stenosis, the first in this patient population ...

After propensity-score adjustment, mean patient age was 67.4 years, about one-third were female, and more than one-quarter were classified as NYHA III/IV at baseline. Over 8 years, there were no ...

A novel therapeutic showed significant promise in slowing aortic valve calcification, potentially extending time until or eliminating need for transcatheter or surgical intervention for stenosis ...

Published last year in the New England Journal of Medicine and reported by TCTMD at that time, the study showed that treating patients who had severe aortic stenosis but no symptoms with TAVI halved ...

For the first time in India, doctors at Rajasthan Hospital, Jaipur have successfully replaced a heart valve through the ...